For more information visit the Company's website at www.freseniusmedicalcare.com. Disclaimer:This release contains forward-looking statements that are subject to various risks and uncertainties. Actual results could differ materially from those described in these forward-looking statements due to various factors, including, but not limited to, changes in business, economic and competitive conditions, legal changes, regulatory approvals, results of clinical studies, foreign exchange rate fluctuations, uncer ...

Core Viewpoint - Fresenius Medical Care (FME) has initiated the first tranche of its EUR 1 billion share buyback program, aimed at enhancing shareholder value as part of its new capital allocation framework [1][2][3]. Group 1: Share Buyback Program - The initial share buyback program totals EUR 1 billion over two years, with the first tranche of up to EUR 600 million set to be completed by April 30, 2026 [1][7]. - The share buyback is a key component of the FME Reignite strategy, which focuses on value creation for shareholders [2][3]. - Regular updates on the share buyback program will be provided on the company's investor relations website [3]. Group 2: Company Overview - Fresenius Medical Care is the leading provider of products and services for individuals with renal diseases, serving approximately 4.2 million patients globally who undergo dialysis treatment [4]. - The company operates a network of 3,676 dialysis clinics, providing treatments for around 300,000 patients worldwide [4]. - Fresenius Medical Care is also a major supplier of dialysis products, including dialysis machines and dialyzers, and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [4].

Core Insights - Fresenius Medical Care AG reported strong operational performance in Q2 2025, with organic revenue growth of 7% and double-digit operating income growth, aligning with the company's full-year financial outlook [1][5][25] - The company experienced a 20% increase in net income for Q2 2025, reaching EUR 225 million, and a 46% increase in net income for H1 2025, totaling EUR 376 million [19][20] Financial Performance - Q2 2025 revenue was EUR 4,792 million, a 1% increase year-on-year, with a 5% increase at constant currency and a 7% organic growth [2][7] - Operating income for Q2 2025 remained stable at EUR 425 million, with a 13% increase in operating income excluding special items to EUR 476 million [13][18] - Basic earnings per share (EPS) increased by 20% to EUR 0.77 in Q2 2025, and by 46% to EUR 1.28 in H1 2025 [20][25] Strategic Initiatives - The FME25+ transformation program generated EUR 58 million in sustainable savings in Q2 2025, with a target of EUR 180 million in annual savings by year-end 2027 [3][5] - The company is executing a portfolio optimization plan to exit non-core assets, which is expected to negatively impact 2025 revenue growth by approximately 1% [4][12] Operational Highlights - Care Enablement revenue increased by 36% in Q2 2025, driven by higher volumes and positive pricing developments [16] - Value-Based Care revenue grew by 22% in Q2 2025, reflecting a significant increase in member months due to contract expansions [9][12] Cash Flow and Leverage - Operating cash flow improved by 75% to EUR 775 million in Q2 2025, with a net leverage ratio of 2.7x [21][23] - Free cash flow increased by 117% to EUR 628 million in Q2 2025 [22] Outlook - Fresenius Medical Care confirmed its fiscal 2025 outlook, expecting positive revenue growth in the low single digits and operating income growth excluding special items in the high teens to high twenties percentage range [25][26]

Core Insights - Fresenius Medical Care (FME) emphasizes data-driven insights and real-world evidence to enhance patient care and improve outcomes for individuals with kidney disease globally [1][2] - The company presents 52 abstracts at the 62nd Congress of the European Renal Association (ERA), focusing on critical areas of nephrology, including home care, critical care, and hemodiafiltration [2][4] Research Highlights - Key presentations include studies on intradialytic arterial oxygen saturation instability, health status in hemodiafiltration versus hemodialysis, and the impact of fluid overload on hospitalization risk [4][5] - The CONVINCE trial analysis links hemodiafiltration to slower health decline and improved quality of life in dialysis patients [4][5] Innovations and Collaborations - FME introduces a novel AI-based recipe recommendation system for dialysis patients, enhancing nutritional management [5] - The company aims to optimize treatment durations in hemodialysis to improve survival outcomes, reinforcing treatment time as a modifiable factor [5] Company Overview - Fresenius Medical Care serves approximately 4.2 million patients worldwide, with around 299,000 patients receiving dialysis treatments through its network of 3,675 clinics [4][6] - The company is a leading provider of dialysis products and is listed on both the Frankfurt Stock Exchange and the New York Stock Exchange [6]

Core Insights - Fresenius Medical Care reported strong operational and financial progress in Q1 2025, confirming its financial outlook for the full year [1][21] - The company achieved organic revenue growth in both segments, with Care Enablement expanding its operating income margin for the first time [1][6] - The FME25 transformation program delivered significant savings, contributing to improved earnings and margin growth [3][7] Financial Performance - Q1 2025 revenue increased by 3% year-on-year to EUR 4,881 million, with organic growth of 5% [2][6] - Operating income rose by 35% to EUR 331 million, with a margin of 6.8%, while net income more than doubled to EUR 151 million [2][17] - Basic earnings per share (EPS) increased by 113% to EUR 0.52, with EPS excluding special items rising by 31% to EUR 0.84 [2][17] Segment Performance - Care Delivery revenue increased by 2% to EUR 3,857 million, while Care Enablement revenue grew by 5% to EUR 1,367 million [8][11] - In the U.S., Care Delivery revenue rose by 6% to EUR 3,302 million, driven by a growing value-based care business [9] - International Care Delivery revenue declined by 19% to EUR 555 million, impacted by closed operations and a decrease in dialysis days [10] Cost Management and Savings - The FME25 program generated EUR 68 million in sustainable savings, with a target of EUR 180 million additional annual savings by year-end 2025 [3][7] - Special items related to portfolio optimization amounted to negative EUR 24 million in Q1 2025 [4][30] - Operating income excluding special items increased by 13% to EUR 457 million, resulting in a margin of 9.4% [13][30] Cash Flow and Leverage - Operating cash flow improved by 28% to EUR 163 million, with a margin of 3.3% [18] - Free cash flow increased to EUR 21 million, and total net debt was reduced to EUR 9,753 million, improving the net leverage ratio to 2.8x [19][19] Outlook - The company expects positive revenue growth in 2025, projecting operating income excluding special items to grow by a high-teens to high-twenties percent rate compared to the prior year [21][22]